---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: AiiM OLE"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: AiiM OLE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 14 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence/aiim-ole"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: AiiM OLE

<a id="heading-3.1.3"></a>

## 3.1.3 AiiM OLE

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Registered purpose of the extension study

> “The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.1-2"></a>

#### Company statement of the extension study objective

> “The OLE study is designed to evaluate the long-term safety and benefit of vonaprument in patients with GA.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.3.1-3"></a>

#### Extension data intended for the label

> “Upon completion of Month 24, all patients will have the option to receive monthly vonaprument treatment in the open-label extension (OLE) study, designed to evaluate the longer-term profile of vonaprument for inclusion in the label.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Registry dates for the extension study

| Milestone | Registry record |
| --- | --- |
| First posted | “2026-09-08” |
| Study start (estimated) | “2026-09-30” |
| Primary completion (estimated) | “2029-07-31” |
| Study completion (estimated) | “2029-07-31” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.2-2"></a>

#### Registered extension study sites

> “Retina Group of Florida”
> “Retina Vitreous Associates of Florida”
> “Cumberland Valley Retina Consultants”
> “Mid Atlantic Retina Specialists”
> “Retina Research Institute at New England Retina Consultants”
> “Asheville Eye Associates - Retina Division”
> “Verum Research, LLC”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.2-3"></a>

#### Extension study identifiers

| Item | Registry record |
| --- | --- |
| Sponsor protocol number | “ANX007-GA-03” |
| EU CT number | “2026-527023-96-00” |
| Acronym | “AiiM OLE” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Registered design of the extension study

> “A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="topic-3.1.3.3-2"></a>

#### Entry into the extension after the ARCHER II Month 24 visit

> “Upon completion of Month 24, all patients have the option to receive monthly vonaprument treatment in the OLE study.”

Source: [Annexon Biosciences ARCHER II expansion press release (2026)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-expands-vonaprument-phase-3-program-geographic-atrophy)

<a id="topic-3.1.3.3-3"></a>

#### Regulatory acceptance of the extension study data

> “There can be no assurance that the FDA and comparable regulatory authorities will accept the data from our Phase 3 program, including the amended dual primary endpoint design or the OLE study, or that such data will be determined sufficient to support approval.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Registered inclusion and exclusion criteria for the extension study

> “Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.”
> “Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.”

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Registered extension study arm and intervention

| Item | Registry record |
| --- | --- |
| Arm | “Participants will receive vonaprument IVT injections every month for 24 months.” |
| Intervention | “Form: solution for injection; Route of Administration: IVT injection” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Registered primary outcome of the extension study

| Outcome | Time frame |
| --- | --- |
| “Number of Participants with Treatment Emergent Adverse Events” | “Through Month 24” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Estimated enrollment in the extension study

| Item | Registry record |
| --- | --- |
| Estimated enrollment | “605” |

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary: extension study not yet started

The AiiM OLE study (NCT07807969) was registered as not yet recruiting, with an estimated start date of September 30, 2026 and an estimated primary completion date of July 31, 2029, so no participant data exist. It is a single-group, open-label design with no masking and no comparator arm, and its registered primary outcome is the number of participants with treatment-emergent adverse events through Month 24; any efficacy observations it yields will lack a concurrent control. Enrollment is limited to participants who completed ARCHER II and had not permanently ceased their assigned masked treatment at or before the Month 24 visit, so the extension population is a selected subset of the ARCHER II population. The company states that the extension is designed to evaluate the “longer-term profile of vonaprument for inclusion in the label”, and its 10-Q states that there is no assurance that regulators will accept data from the OLE study.

Source: [ClinicalTrials.gov NCT07807969](https://clinicaltrials.gov/study/NCT07807969); [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
